Canada's Drug Agency Backs Public Reimbursement for Biogen's Alzheimer's Drug LEQEMBI
BIIB sits 65% above its 52-week low of $131.52.
Summary
Canada's Drug Agency issued a final positive recommendation supporting public reimbursement of LEQEMBI for early Alzheimer's disease. This is a key regulatory milestone that clears a major hurdle for market access in Canada, where over 770,000 people live with dementia. The recommendation follows a reconsideration and moves the drug closer to provincial coverage, though negotiations through the pan-Canadian Pharmaceutical Alliance and individual provincial decisions are still pending. For Biogen, this expands the commercial opportunity for its Alzheimer's franchise, which has been a focus of recent positive developments including FDA approvals for subcutaneous dosing. The news is incremental but meaningful for a company trading near its 52-week high.
At the time of this announcement, BIIB was trading at $216.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $32B. The 52-week trading range was $131.52 to $222.85. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.